TherapeuticsMD Now Covered by JMP Securities (TXMD)
Research analysts at JMP Securities initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $7.00 price target on the stock. JMP Securities’ price objective points to a potential upside of 38.07% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group initiated coverage on shares of TherapeuticsMD in a research note on Thursday, May 29th. They set a “buy” rating and a $7.00 price target on the stock. Analysts at Noble Financial raised their price target on shares of TherapeuticsMD from $9.00 to $13.00 in a research note on Thursday, April 17th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, TherapeuticsMD presently has an average rating of “Buy” and a consensus price target of $8.75.
In other TherapeuticsMD news, Director Cooper C. Collins purchased 20,000 shares of TherapeuticsMD stock in a transaction dated Thursday, June 5th. The stock was purchased at an average price of $3.84 per share, with a total value of $76,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 5.07 on Tuesday. TherapeuticsMD has a one year low of $2.03 and a one year high of $9.01. The stock has a 50-day moving average of $4.02 and a 200-day moving average of $5.32. The company’s market cap is $737.4 million.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.08 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. On average, analysts predict that TherapeuticsMD will post $-0.28 earnings per share for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.